Potentially inappropriate prescribing in multimorbid and polymedicated older adults with AF: A Systematic Review and Meta-Analysis

Li H, Song X, Liang Y, et al. Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a global burden of disease study, 2019. BMC Public Health. 2022;22(1):2015. https://doi.org/10.1186/s12889-022-14403-2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–21. https://doi.org/10.1177/1747493019897870. Chen MA. Multimorbidity in older adults with atrial fibrillation. Clin Geriatr Med. 2016;32(2):315–29. https://doi.org/10.1016/j.cger.2016.01.001. Zhang J, Johnsen SP, Guo Y, et al. Epidemiology of atrial fibrillation: geographic/ecological risk factors, age, sex, genetics. Card Electrophysiol Clin. 2021;13(1):1–23. https://doi.org/10.1016/j.ccep.2020.10.010. Kornej J, Borschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4–20. https://doi.org/10.1161/CIRCRESAHA.120.316340. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results [Internet]. Institute for Health Metrics and Evaluation (IHME). 2020. Available from: https://vizhub.healthdata.org/gbd-results/. Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes. 2022;8(2):187–94. https://doi.org/10.1093/ehjqcco/qcaa093. Proietti M, Romiti GF, Olshansky B, et al. Comprehensive management With the ABC (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc. 2020;9(10): e014932. https://doi.org/10.1161/jaha.119.014932. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306(17):1018–22. https://doi.org/10.1056/NEJM198204293061703. Alexander KP, Brouwer MA, Mulder H, et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: insights from the ARISTOTLE trial. Am Heart J. 2019;208:123–31. https://doi.org/10.1016/j.ahj.2018.09.017. LaMori JC, Gross HJ, Patel AA, et al. Burden of comorbidities among patients with atrial fibrillation. Value Health. 2011;14(3):A34-A. Proietti M, Marzona I, Vannini T, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc. 2019;94(12):2427–36. https://doi.org/10.1016/j.mayocp.2019.06.012. Kozieł M, Simovic S, Pavlovic N, et al. Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. Ann Med. 2021;53(1):17–25. https://doi.org/10.1080/07853890.2020.1799241. Lip GYH, Genaidy A, Tran G, et al. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. Thromb Haemost. 2022;122(1):142–50. https://doi.org/10.1055/a-1467-2993. Dalgaard F, Xu H, Matsouaka RA, et al. Management of atrial fibrillation in older patients by morbidity burden: insights from get with the guidelines-atrial fibrillation. J Am Heart Assoc. 2020;9(23): e017024. https://doi.org/10.1161/JAHA.120.017024. Romiti GF, Proietti M, Bonini N, et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022;122(12):2030–41. https://doi.org/10.1055/s-0042-1756355. Gallagher C, Nyfort-Hansen K, Rowett D, et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2020. https://doi.org/10.1136/openhrt-2020-001257. Castillo-Páramo A, Clavería A, Verdejo González A, et al. Inappropriate prescribing according to the STOPP/START criteria in older people from a primary care setting. Eur J Gen Pract. 2014;20(4):281–9. https://doi.org/10.3109/13814788.2014.899349. Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019. https://doi.org/10.1186/s12877-019-1168-1. Rothberg MB, Pekow PS, Liu F, et al. Potentially inappropriate medication use in hospitalized elders. J Hosp Med. 2008;3(2):91–102. https://doi.org/10.1002/jhm.290. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29(6):437–52. https://doi.org/10.2165/11632610-000000000-00000. Guaraldo L, Cano FG, Damasceno GS, et al. Inappropriate medication use among the elderly: a systematic review of administrative databases. BMC Geriatr. 2011. https://doi.org/10.1186/1471-2318-11-79. Lozano-Montoya I, Velez-Diaz-Pallares M, Delgado-Silveira E, et al. Potentially inappropriate prescribing detected by STOPP-START criteria: are they really inappropriate? Age Ageing. 2015;44(5):861–6. https://doi.org/10.1093/ageing/afv079. Lucchetti G, Lucchetti AL. Inappropriate prescribing in older persons: a systematic review of medications available in different criteria. Arch Gerontol Geriatr. 2017;68:55–61. https://doi.org/10.1016/j.archger.2016.09.003. Wallace E, McDowell R, Bennett K, et al. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2017;72(2):271–7. https://doi.org/10.1093/gerona/glw140. Tommelein E, Mehuys E, Petrovic M, et al. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71(12):1415–27. https://doi.org/10.1007/s00228-015-1954-4. Panel BtAGSBCUE. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145. Lopez-Rodriguez JA, Rogero-Blanco E, Aza-Pascual-Salcedo M, et al. Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: a cross-sectional study. PLoS ONE. 2020;15(8): e0237186. https://doi.org/10.1371/journal.pone.0237186. Curtin D, Gallagher PF, O’Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019. https://doi.org/10.1177/2042098619829431. Hanlon JT, Schmader KE. The Medication Appropriateness Index: a clinimetric measure. Psychother Psychosom. 2022;91(2):78–83. https://doi.org/10.1159/000521699. Grymonprez M, Steurbaut S, De Backer TL, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11: 583311. https://doi.org/10.3389/fphar.2020.583311. Mekonnen AB, Redley B, de Courten B, et al. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021. https://doi.org/10.1111/bcp.14870. Moudallel S, Steurbaut S, Cornu P, et al. Appropriateness of (D)OAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.01220. Motter FR, Fritzen JS, Hilmer SN, et al. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74(6):679–700. https://doi.org/10.1007/s00228-018-2446-0. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https://doi.org/10.1186/s13643-021-01626-4. Amrouch C, Vauterin D, Amrouch S, et al. Potentially inappropriate medication use in multimorbid and polymedicated older adults with atrial fibrillation: a systematic review and meta-analysis. PROSPERO 2021 CRD42021283474 2021. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021283474. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021. Johnston MC, Crilly M, Black C, et al. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019;29(1):182–9. https://doi.org/10.1093/eurpub/cky098. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017. https://doi.org/10.1186/s12877-017-0621-2. Sirois C, Domingues NS, Laroche ML, et al. Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy. 2019. https://doi.org/10.3390/pharmacy7030126. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276–82. Bramer W, Bain P. Updating search strategies for systematic reviews using EndNote. J Med Libr Assoc. 2017;105(3):285–9. https://doi.org/10.5195/jmla.2017.183. Kmet LL, Robert.; Cook Linda. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. HTA Initiative 2004. Ryan R HS, Prictor M, McKenzie J. Cochrane consumers and communication review group. Study Quality Guide. 2013. http://cccrg.cochrane.org/authorresources. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80. https://doi.org/10.1001/jama.295.6.676. Jonathan J Deeks JPH, Douglas G Altman; on behalf of the Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3, 20222022. Akao M, Shimizu W, Atarashi H, et al. Oral Anticoagulant use in elderly japanese patients with non-valvular atrial fibrillation—subanalysis of the ANAFIE Registry. Circ Rep. 2020;2(10):552–9. https://doi.org/10.1253/circrep.CR-20-0082. Antoniazzi S, Ardoino I, Proietti M, et al. Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM-AF cluster randomized clinical trial. Br J Clin Pharmacol. 2019;85(9):2134–42. https://doi.org/10.1111/bcp.14029. Capiau A, De Backer T, Grymonprez M, et al. Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation according to the drug labelling and the EHRA Practical Guide. Int J Cardiol. 2021;328:97–103. https://doi.org/10.1016/j.ijcard.2020.11.062. Franchi C, Antoniazzi S, Proietti M, et al. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. Br J Clin Pharmacol. 2018;84(9):2010–9. https://doi.org/10.1111/bcp.13631. Hupfer M, Gosch M. Anticoagulation in very old patients with atrial fibrillation (AVOPA): a descriptive observational study. Drugs Real World Outcomes. 2021;8(4):603–14. https://doi.org/10.1007/s40801-021-00263-6. Jackson LR 2nd, Schrader P, Thomas L, et al. Dosing of direct oral anticoagulants in patients with moderate chronic kidney disease in US clinical practice: results from the outcomes registry for better informed treatment of AF (ORBIT-AF II). Am J Cardiovasc Drugs. 2021;21(5):553–61. https://doi.org/10.1007/s40256-021-00473-x. Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med. 2010;21(6):516–23. https://doi.org/10.1016/j.ejim.2010.07.014. Mazzone A, Bo M, Lucenti A, et al. The role of comprehensive geriatric assessment and functional status in evaluating the patterns of antithrombotic use among older people with atrial fibrillation. Arch Gerontol Geriatr. 2016;65:248–54. https://doi.org/10.1016/j.archger.2016.04.008. Raccah BH, Erlichman Y, Pollak A, et al. Prescribing errors with direct oral anticoagulants and their impact on the risk of bleeding in patients with atrial fibrillation. J Cardiovasc Pharmacol Ther. 2021;26(6):601–10. https://doi.org/10.1177/10742484211019657. Spinewine A, Swine C, Dhillon S, et al. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. J Am Geriatr Soc. 2007;55(5):658–65. https://doi.org/10.1111/j.1532-5415.2007.01132.x. Wang Y, Singh S, Bajorek B. Old age, high risk medication, polypharmacy: a “trilogy” of risks in older patients with atrial fibrillation. Pharm Pract (Granada). 2016;14(2):706. https://doi.org/10.18549/PharmPract.2016.02.706. Li RJ, Caughey GE, Shakib S. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. J Thromb Thrombolysis. 2022;53(2):425–35. https://doi.org/10.1007/s11239-021-02528-x. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51. https://doi.org/10.1016/0895-4356(92)90144-c. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157(14):1531–6. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24. https://doi.org/10.1001/archinte.163.22.2716. Wenger NS, Shekelle PG. Assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135(8 Pt 2):642–6. https://doi.org/10.7326/0003-4819-135-8_part_2-200110161-00002. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):546S-592S. https://doi.org/10.1378/chest.08-0678. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. https://doi.org/10.1093/eurheartj/ehs253. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104. https://doi.org/10.1161/CIR.0000000000000040. Fick D, Semla T, Beizer J, et al. American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31. https://doi.org/10.1111/j.1532-5415.2012.03923.x. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543-U39. https://doi.org/10.3238/arztebl.2010.0543. Panel BtAGSBCUE. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46. https://doi.org/10.1111/jgs.13702. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. https://doi.org/10.1093/eurheartj/ehw210. EMA. Human medicine European public assessment report. https://www.ema.europa.eu/en/medicines. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507. https://doi.org/10.1093/europace/euv309. Pharmaceutical Care Network Europe Foundation. PCNE Classification scheme for Drug-Related Problems V8.03. 2019. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93. https://doi.org/10.1093/eurheartj/ehy136. Australian Product Information Eliquis (Apixaban) Bristol-Myers Squibb Australia Pty Ltd, Victoria, Australia [Approved Australian Product Information, approved 21 July 2011, date of revision 05 August 2019]. 2019. Australian Product Information Pradaxa (dabigatran etexilate) capsule Boehringer Ingelheim Pty Limited, Australia [Approved Australian Product Information, approved 24 November 2008, date of revision 07 February 2020]. 2020. Australian Product Information Xarelto (rivaroxaban) Bayer Australia Ltd, Australia [Approved Australian Product Information, approved 24 November 2008, date of revision 24 December 2018]. 2018. Clark-Carter D. Measures of central tendency. Int Encyclopedia Educ. 2010. https://doi.org/10.1016/B978-0-08-044894-7.01343-9. Thomas H CCE, Leiserson; Ronald L, Rivest.; Clifford, Stein. Introduction to Algorithms. Press M, editor 2001. William J ME, Read; Teri, McComber; Alyson, Mahar; Krista, Ritchie. Applied Statistics in Healthcare Research. Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13): e017559. https://doi.org/10.1161/JAHA.120.017559. Zhu J, Alexander GC, Nazarian S, et al. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy. 2018;38(9):907–20. https://doi.org/10.1002/phar.2158. Ibanez L, Sabate M, Vidal X, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): a cross-national drug utilization study. Br J Clin Pharmacol. 2019;85(11):2524–39. https://doi.org/10.1111/bcp.14071. Andrade JG, Krahn AD, Skanes AC, et al. Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol. 2016;32(6):747–53. https://doi.org/10.1016/j.cjca.2015.09.023. Miyazaki M, Matsuo K, Uchiyama M, et al. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci. 2020. https://doi.org/10.1186/s40780-020-0157-z. Ding M, Fratiglioni L, Johnell K, et al. Atrial fibrillation and use of antithrombotic medications in older people: a population-based study. Int J Cardiol. 2017;249:173–8. https://doi.org/10.1016/j.ijcard.2017.07.012. Migliavaca CB, Stein C, Colpani V, et al. Meta-analysis of prevalence: I(2) statistic and how to deal with heterogeneity. Res Synth Methods. 2022;13(3):363–7. https://doi.org/10.1002/jrsm.1547. Hunter JP, Saratzis A, Sutton AJ, et al. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol. 2014;67(8):897–903. https://doi.org/10.1016/j.jclinepi.2014.03.003. Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21(1):189. https://doi.org/10.1186/s12874-021-01381-z. Wu X, Hu L, Liu J, et al. Off-label underdosing or overdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Front Cardiovasc Med. 2021;8: 724301. https://doi.org/10.3389/fcvm.2021.724301. Santos J, Antonio N, Rocha M, et al. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86(3):533–47. https://doi.org/10.1111/bcp.14127. Shen NN, Zhang C, Hang Y, et al. Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: an epidemiological meta-analysis. Front Pharmacol. 2021;12: 581293. https://doi.org/10.3389/fphar.2021.581293. Caso V, de Groot JR, Sanmartin Fernandez M, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109(3):178–85. https://doi.org/10.1136/heartjnl-2022-321114. Romiti GF, Proietti M, Vitolo M, et al. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med. 2022;20(1):326. https://doi.org/10.1186/s12916-022-02526-7. Prados-Torres A, Calderon-Larranaga A, Hancco-Saavedra J, et al. Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014;67(3):254–66. https://doi.org/10.1016/j.jclinepi.2013.09.021. Fumagalli S, Chen J, Dobreanu D, et al. The role of the Arrhythmia Team, an integrated, multidisciplinary approach to treatment of patients with cardiac arrhythmias: results of the European Heart Rhythm Association survey. Europace. 2016;18(4):623–7. https://doi.org/10.1093/europace/euw090. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627–8. https://doi.org/10.1038/nrcardio.2017.153. Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the “Atrial Fibrillation Better Care” Pathway in Patients with Atrial Fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2022;122(3):406–14. https://doi.org/10.1055/a-1515-9630. Proietti M, Lip GYH, Laroche C, et al. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORPAtrial Fibrillation General Long-Term (AFGen LT) Registry. Europace. 2021;23(2):174–83. https://doi.org/10.1093/europace/euaa274. Kotalczyk A, Guo YT, Stefil M, et al. Effects of the atrial fibrillation better care pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy: a report from the ChiOTEAF Registry. Am Heart Assoc. 2022. https://doi.org/10.1161/JAHA.121.024319. Yao Y, Guo YT, Lip GYH, et al. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity the mAFA-II randomized clinical trial. JAMA Netw Open. 2021. https://doi.org/10.1001/jamanetworkopen.2021.40071. Chao TF, Joung B, Takahashi Y, et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2022;122(1):20–47. https://doi.org/10.1055/s-0041-1739411. Johnsen SP, Proietti M, Maggioni AP, et al. A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. Eur Heart J. 2022;43(31):2916–8. https://doi.org/10.1093/eurheartj/ehac265. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48. https://doi.org/10.18637/jss.v036.i03.